Slingshot members are tracking this event:

FDA Grants Rare Pediatric Disease Designation to Sangamo's (SGMO) SB-318 for Mucopolysaccharidosis Type I (MPS I)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 27, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda, Rare Pediatric Disease Designation, Sb-318, Mucopolysaccharidosis Type I, Mps I